GetTopicDetailResponse(id=68bd12232439, topicName=非臨床安全性評估, introduction=, content=抗體偶聯(lián)藥物 非臨床安全性評估, image=null, comments=0, allHits=336, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sat Dec 14 18:11:05 CST 2024, time=2024-12-14, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=499390, tagList=[TagDto(tagId=499390, tagName=非臨床安全性評估)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2242378, encodeId=a0b022423e81f, content=<a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗體偶聯(lián)藥物#</a> <a href='/topic/show?id=68bd12232439' target=_blank style='color:#2F92EE;'>#非臨床安全性評估#</a>, objectTitle=ADC非臨床安全性評價的考量因素, objectType=article, longId=853716, objectId=d001853e16a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20241213/1734088111083_8538692.jpg, objectUrl=/article/show_article.do?id=d001853e16a6, replyNumber=0, likeNumber=40, createdTime=2024-12-14, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=d001853e16a6, moduleTitle=ADC非臨床安全性評價的考量因素, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d001853e16a6)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-12-14發(fā)表于陜西省
